Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

Regarding this post:

Kessler was an MD/JD that was dismissed from UCSF in 2007.

DeGrado is a Chem PhD who joined UCSF in 2011.

Their fields don't overlap nor did their tenure at UCSF. They probably have never heard of each other until 2020 if at all.

...overlooked a few FACTS that have been left out:

... Dr. Kessler was an MD/JD that was dismissed from UCSF in 2007...but was re-hired shortly thereafter (when it was determined that his whistle-blower allegations were indeed correct), and

... Dr. Kessler has been Professor of Pediatrics and Epidemiology and Biostatistics at UCSF, ever since and during Dr. DeGrado's 10-year tenure at UCSF, and

... Dr. Kessler is a key advisor in the "more than $3 billion to efforts aimed at expediting the “discovery, development and manufacturing” of antiviral medicines to treat not only Covid-19 but also viruses that could cause future pandemics."

(What compound is being studied and tested by RBL's as an "antiviral medicines to treat not only Covid-19 but also viruses that could cause future pandemics"?)

Also it should be noted that Kessler has been involved in Research since before UCSF (below)...and is on the board of Ellodi Pharmaceuticals. (appointed in fall of 2020), privately held and located in Lawrenceville, NJ.

https://ellodipharma.com/ellodi-pharmaceuticals-announces-fast-track-designation-granted-by-the-fda-to-apt-1011-for-the-treatment-of-eosinophilic-esophagitis-eoe/

Company is a gastroenterology-focused specialty pharmaceutical company

Primary research is on Eosinophilic esophagitis (e-o-sin-o-FILL-ik uh-sof-uh-JIE-tis) is a chronic immune system disease in which a type of white blood cell (eosinophil) builds up in the lining of the tube that connects your mouth to your stomach (esophagus). This buildup, which is a reaction to foods, allergens or acid reflux, can inflame or injure the esophageal tissue. Damaged esophageal tissue can lead to difficulty swallowing or cause food to get stuck when you swallow.

Eosinophilic esophagitis has been identified only since the early 90s, but is now considered a major cause of digestive system (gastrointestinal) illness. Research is ongoing and will likely lead to revisions in the diagnosis and treatment of eosinophilic esophagitis.

DO WE KNOW OF A COMPOUND ... that addresses "Inflammatory" and "Gastrointestinal" conditions? (Brilacidin?)

DO WE KNOW THE FORMULATOR/DEVELOPER OF BRILACIDIN? ... (Dr. DEGRADO)

DO WE KNOW IF BOTH Research Doctors DEGRADO and KESSLER who work at UCSF might know each other...maybe intimately?

Might Drs Kessler have reason to be educated and more than familiar with DeGrado and Brilacidin and have reasons to professionally speak to one another?




Some of Kessler's Research Activities:

General Clinical Research Center
NIHM01RR000079Dec 1, 1974 - Mar 31, 2009
Role: Principal Investigator

Some of Kessler's Publications:

Tsimring L, Levine H, Kessler D. RNA virus evolution via a fitness-space model. Physical Review Letters. 1996;76:4440–4443. - PubMed

Cohen E, Kessler D, Levine H. Recombination dramatically speeds up evolution of finite populations. Physical Review Letters. 2005;94:98102. - PubMed

Cohen E, Kessler D, Levine H. Analytic approach to the evolutionary effects of genetic exchange. Physical Review E. 2006;73:16113. - PubMed

Related article:

"Updated Jun 17, 2021, 04:07pm EDT
TOPLINE The Biden Administration plans to invest more than $3 billion to efforts aimed at expediting the “discovery, development and manufacturing” of antiviral medicines to treat not only Covid-19 but also viruses that could cause future pandemics, the U.S. Department of Health and Human Services announced on Thursday."


"Dr. David Kessler, the chief science officer of Biden’s Covid-19 response team, told the New York Times the hope “is that we can get an antiviral by the end of the fall that can help us close out this chapter of the epidemic.”

"The National Institutes of Health confirmed Thursday it will “evaluate, prioritize and advance antiviral candidates'' to Phase 2 clinical trials."